Samir Parekh, MD

“We do have some interesting correlative results from these patients, as they've gone through sequential therapies, that are quite eye popping and surprising even to scientists and immunologists alike at our institution. We also have a concurrent publication that should be coming out soon on what happens after CAR T progression and this is another important topic, especially as we have 2 approvedCAR Ts that are being used now in the US.”

New research out of Mount Sinai’s Tisch Cancer Institute published in

has revealed that sequential use of different T cell redirection therapies, including chimeric antigen receptor (CAR) T-cell therapies, after relapsing on bispecific antibodies (BiAb) led to deep and durable responses in patients with relapsed/refractory multiple myeloma.

 spoke with Samir Parekh, MD, the director of translational research at the institute, to learn more about the surprising findings of the new study, including the preserved efficacy of secondary T-cell redirection therapies further down the line and not just as a next-line therapy. He discussed the relevance of the research as more CAR T-cell therapies are approved and come to the market.

Mouhieddine TH, Oekelen OV, Melnekoff DT, et al. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients. 

 Published online August 2, 2022. doi: 10.1182/bloodadvances.2022007923

Videos

The director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market. 

Samir Parekh, MD, on Surprising Efficacy of Sequential T-Cell Redirection Therapy in Multiple Myeloma 

“The question to us as both clinicians and researchers was, how can we treat these patients; what will be the best sequential therapy after the bispecific when patients relapse? And this is important because it could inform how we could move them in earlier lines of therapy and what to do with patients that relapse even if they get it in earlier lines of therapy.”

Sequential use of different T cell redirection therapies, including chimeric antigen receptor (CAR) T-cell therapies, after relapsed on bispecific antibodies (BiAb) led to deep and durable responses in patients with relapsed/refractory multiple myeloma, according to new research published in 

 spoke with Samir Parekh, MD, to learn more about the new research out of at Mount Sinai’s Tisch Cancer Institute. Parekh serves as director of translational research in myeloma and co-leader of the Cancer Clinical Investigation program at The Tisch Cancer Institute andis a member of the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai. Parekh discussed the research that his team conducted and the positive progression-free survival findings for patients on sequential T-cell redirection therapies.

Published online August 2, 2022. doi: 10.1182/bloodadvances.2022007923

The director of translational research in myeloma at the Tisch Cancer Institute discussed positive findings, including a 30-month PFS in study participants. 

Samir Parekh, MD, on Improving Survival in Multiple Myeloma With Sequential T-Cell Redirection Therapies 

“Once a patient relapses several times, they start running out of FDA-approved treatment options. And these new, both cellular and bispecific antibody, agents that are on the cusp of being approved are providing hope for those patients. In fact, the initial results from the studies are so promising that they are now being used or tested at least in earlier lines of treatment with combinations of other drugs that are being used to treat myeloma. And that's where our research comes in.”

Sequential use of different T cell redirection therapies, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (BiAb) led to deep and durable responses in patients with relapsed/refractory multiple myeloma following relapse after BiAb therapy, according to new research out of at Mount Sinai’s Tisch Cancer Institute published in 

 spoke with Samir Parekh, MD, director of translational research in myeloma and co-leader, Cancer Clinical Investigation program, The Tisch Cancer Institute, and member, Icahn Genomics Institute, Icahn School of Medicine, Mount Sinai, to learn more about the unmet needs for patients whose multiple myeloma relapses several times and the questions that remain to be investigated with sequential T cell redirection therapies.

The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies. 

Samir Parekh, MD

Articles

Samir Parekh, MD, on Surprising Efficacy of Sequential T-Cell Redirection Therapy in Multiple Myeloma

Samir Parekh, MD, on Improving Survival in Multiple Myeloma With Sequential T-Cell Redirection Therapies

Samir Parekh, MD, on Investigating Treatment Options for Relapsed Myeloma